Intervention

endocrinotherapy（doctor's choice）

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

2 shown

Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNCT07766772 · 2026-09-30

NOT_YET_RECRUITING

Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With PalbociclibNCT05464173 · 2022-07-01

Common conditions

Advanced Breast Cancer1 Breast Cancer1 HER2 + Breast Cancer1

Leading sponsors

Biyun Wang, MD1 Fujian Cancer Hospital1

Trial status mix

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.